It is announced today (26 July 2017) that Steve Oldfield will take up the role of Chief Commercial Officer, a newly created position, this coming October.
Steve Oldfield will be joining the Government Commercial Function and taking up a post as the CCO at the Department of Health. His initial focus will be the creation and development of the commercial strategy that will underpin upcoming negotiations with a variety of commercial suppliers, including key engagements with the pharmaceutical industry in particular over the PPRS scheme, under which we presently spend circa £8 billion a year.
Reporting to DH’s Permanent Secretary, Chris Wormald, he will be the most senior commercial manager within the health family and will lead the development of commercial capability and sharing of commercial best practice across the wider health family to the benefit of the whole system. He will be employed centrally as one of the new cohort of senior commercial managers tasked with improving the delivery and cost performance of our supply chain and will report functionally to Gareth Rhys Williams, Government Chief Commercial Officer, and be responsible for ensuring DH plays a leading role in the wider Government Commercial Function.
Steve has more than 25 years’ experience in the healthcare industry. He is currently Chief Operating Officer for PGT, a consumer health joint venture between Procter & Gamble and Teva, based in Geneva. Among his previous roles he has been the UK Managing Director for both Sanofi and Teva, as well as senior roles in Asia and Latin America. Steve has been involved for a number of years with industry-government initiatives, having served on the Board of the ABPI and co-chaired committees looking at the introduction and adoption of new medicines.
Chris Wormald, Permanent Secretary, Department of Health says:
I am delighted that, working with GCF, we have been able to secure Steve Oldfield as our new CCO. We face a number of commercial challenges across the health family, not least putting in place the next generation of the medicines pricing scheme, but we see huge opportunities for better delivery for patients and better value for money for the taxpayers from improved commercial skills and experience.
Paul Baumann, Chief Financial Officer, NHS England says:
Building strong commercial capability is a high priority for NHS England, as we seek to provide access to the best drugs and treatments for patients in a way which secures the best possible value. We welcome this new appointment as part of the department’s initiatives in this area and look forward to close collaboration over the coming years.
Gareth Rhys Williams, Government Chief Commercial Officer says:
As we continue to improve our commercial capability across government, I’m very pleased to have attracted Steve to this key role in Health. He brings deep knowledge of the pharmaceutical industry, which will be very valuable as we start to work with them on the next iteration of the £8 billion per annum medicines pricing scheme.
Steve Oldfield says:
I am delighted to be joining the Department of Health, especially at such an exciting time. Demands on the health system have never been greater, and I hope to be able to bring my previous commercial experience to bear on the activities of the department. In particular, I look forward to working collaboratively across the department, the NHS and the life sciences to find new ways of working for the benefit of patients and the health economy.